logo
episode-header-image
Sep 2023
11m 14s

330. Guidelines: 2021 ESC Cardiovascular...

CARDIONERDS
About this episode

The following question refers to Section 4.5 of the 2021 ESC CV Prevention Guidelines. The question is asked by Dr. Maryam Barkhordarian, answered first by pharmacy resident Dr. Anushka Tandon, and then by expert faculty Dr. Noreen Nazir.

Dr. Nazir is Assistant Professor of Clinical Medicine at the University of Illinois at Chicago, where she is the director of cardiac MRI and the preventive cardiology program.

The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardiovascular Nurses Association.

Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values.



Question #33

Mr. V is a 37-year-old man who presents to clinic after a recent admission for anterior STEMI and is status-post emergent percutaneous intervention to the proximal LAD. He has mixed hyperlipidemia and a 10 pack-year history of (current) tobacco smoking. Which of the following points related to tobacco use is LEAST appropriate for today’s visit?

A

Providing assessment and encouragement for smoking cessation, even if for only a 30-second “very brief advice” intervention.

B

Reviewing and offering pharmacotherapy support options for smoking cessation if Mr. V expresses readiness to quit today.

C

Recommending a switch from traditional cigarettes to e-cigarettes as a first step towards cessation, as e-cigarettes are safer for use.

D

Discussing that smoking cessation is strongly recommended for all patients, regardless of potential weight gain.



Answer #33

Explanation

Answer C is LEAST appropriate and therefore is the correct answer.

Answer C is not appropriate. Although e-cigarettes may be more effective than nicotine replacement therapy (NRT) for smoking cessation, the long-term effects of e-cigarettes on cardiovascular and pulmonary health are unknown. According to the 2019 ACC/AHA prevention guidelines, e-cigarettes may increase the risk of CV and pulmonary diseases; their use has been reportedly associated with arrhythmias and hypertension. Therefore, neither the ESC nor ACC/AHA suggest clinicians recommend e-cigarettes over traditional cigarettes to patients.

Answer A: Smoking cessation is one of the most effective CVD risk-lowering preventive measures, with significant reductions in (repeat) myocardial infarctions or death. ESC guidelines emphasize the importance of encouraging smoking cessation even in settings where time is limited. “Very brief advice” on smoking is a proven 30-second clinical intervention, developed in the UK, which identifies smokers, advises them on the best method of quitting, and supports subsequent quit attempts. While ESC does not explicitly suggest a frequency of assessment, the 2019 ACC/AHA guidelines specifically recommend that “all adults should be assessed at every healthcare visit for tobacco use and their tobacco use status recorded as a vital sign to facilitate tobacco cessation.”

Answer B: The ESC suggests (class 2) that offering follow-up support, nicotine replacement therapy, varenicline, and bupropion individually or in combination should be considered in smokers. A meta-analysis of RCTs in patients with ASCVD reflects that varenicline (RR 2.6), bupropion (RR 1.4), telephone therapy (RR 1.5), and individual counselling (RR 1.6) all increased quit rates versus placebo; NRT therapies were well-tolerated but had inconclusive effects on quit rates (RR 1.22 with 95% CI 0.72-2.06). The 2019 ACC/AHA recommendation to combine behavioral and pharmacotherapy interventions to maximize quit rates is a class 1 recommendation.

Answer D: The ESC gives a class 1 recommendation to recommending smoking cessation regardless of weight grain. Smokers who quit may expect an average weight gain of 5 kg, but the health benefits of tobacco cessation (both CVD and non-CVD related) consistently outweigh risks from weight gain. Weight gain does not lessen the ASCVD benefits of cessation. The 2019 ACC/AHA guidelines do not specifically comment on weight considerations with smoking cessation.

Main Takeaway

Stopping smoking is potentially the most effective of all preventive measures. All smoking of tobacco should be stopped, as tobacco use is strongly and independently causal of ASCVD (Class 1). Smoking cessation should be regularly assessed for and encouraged, and pharmacotherapy and follow-up support for cessation should be considered for patients who are ready for a quit attempt.

Guideline Loc.

Section 4.5, Table 9

CardioNerds Decipher the Guidelines – 2021 ESC Prevention Series
CardioNerds Episode Page
CardioNerds Academy
Cardionerds Healy Honor Roll

CardioNerds Journal Club
Subscribe to The Heartbeat Newsletter!
Check out CardioNerds SWAG!
Become a CardioNerds Patron!

Up next
Yesterday
421. Case Report: Switched at Birth: A Case of Congenital Heart Disease Presenting in Adulthood – New York Presbyterian Queens
CardioNerds (Dr. Claire Cambron and Dr. Rawan Amir) join Dr. Ayan Purkayastha, Dr. David Song, and Dr. Justin Wang from NewYork-Presbyterian Queens for an afternoon of hot pot in downtown Flushing. They discuss a case of congenital heart disease presenting in adulthood. Expert co ... Show More
29m 12s
Jun 20
420. Cardio-Rheumatology: Cardiovascular Multimodality Imaging & Systemic Inflammation with Dr. Monica Mukherjee
In this episode, CardioNerds Dr. Gurleen Kaur, Dr. Richard Ferraro, and Dr. Jake Roberts are joined by Cardio-Rheumatology expert, Dr. Monica Mukherjee, to discuss the role of utilizing multimodal imaging for cardiovascular disease risk stratification, monitoring, and management ... Show More
17m 54s
Jun 4
419. HFpEF in Women with Dr. Anu Lala and Dr. Martha Gulati
In this episode, CardioNerds Dr. Anna Radakrishnan and Dr. Apoorva Gangavelli are joined by prevention expert Dr. Martha Gulati and heart failure expert Dr. Anu Lala to discuss heart failure with preserved ejection fraction (HFpEF), a multifactorial, evolving challenge, particula ... Show More
24m 40s
Recommended Episodes
May 2020
COVID-19 Digest: Could Cigarette Smoking Actually be Protective Against COVID?
Host: Elizabeth Esty, MD. Smoking is known to increase both susceptibility and severity of all manner of colds and pneumonias, so you’d think the world's 1.1 billion smokers would be at risk in this pandemic of what at first seemed to be a just a respiratory virus.  What’s more, ... Show More
18m 25s
Nov 2023
ZFA TALK: Das ABC des Rauchstopps
mit Prof. Dr. Daniel Kotz, Suchtforscher (00:57) Rauchverhalten in Deutschland | (04:12) Gesundheitliche Folgen des Rauchens | (06:04) Suchtproblematik | (10:16) Rolle der Hausarztpraxis | (14:15) Aktuelle Leitlinienempfehlungen zur Beratung und pharmakologischen Optionen | (18:3 ... Show More
28m 1s
Feb 2024
AHA Late-Breaker ARTESiA: Apixaban for the Prevention of Stroke in Patients With Subclinical AF
Continuous cardiac monitoring detects brief, asymptomatic, heart rhythm abnormalities in one-third of older individuals and these symptoms are associated with an increased risk of stroke.  The ARTESiA trial clearly demonstrates that use of the blood thinner apixaban reduces patie ... Show More
13m 33s
Dec 2022
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2022.2 Part 2
Dr. Dwight Owen presents the first update to the ASCO living guideline on stage IV NSCLC with driver alterations. He identifies the latest trials that informed this update, and the updated evidence-based options for second- or later-line therapies for patients with advanced non-s ... Show More
8m 24s
Apr 2023
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2023.1 Part 2
Dr. Dwight Owen is back on the ASCO Guidelines podcast, discussing the latest updates to the ASCO living guidelines for stage IV NSCLC. In Part 2, Dr. Owen presents the update for stage IV NSCLC with driver alterations. He reviews new evidence from KRYSTAL-1, and reviews a new re ... Show More
9m 21s
Apr 2023
VTE Prophylaxis and Treatment in Patients with Cancer Guideline Update
Dr. Nigel Key and Dr. Anna Falanga join us for a conversation on the updated ASCO VTE prophylaxis and treatment in patients with cancer guideline. They discuss recent evidence assessing apixaban for VTE treatment in patients with cancer and evaluating direct factor Xa inhibitors ... Show More
14m 5s
Jan 2024
Review of the Cardiac Arrhythmia Suppression Trial (CAST)
NEJM 1991;324:781-788Background A hallmark of post-myocardial infarction (MI) care in the 1980’s was the monitoring and suppression of premature ventricular contractions (PVCs) via use of antiarrhythmic drugs. The practice was based on pathophysiologic rationale that PVC burden i ... Show More
6m 58s
May 2024
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.1
Dr. Jyoti Patel discusses the latest update to the stage IV NSCLC with driver alterations living guideline, specifically for patients with EGFR or ROS1 alterations. She shares the latest recommendations based on recently published evidence, such as the FLAURA2, MARIPOSA-2, and TR ... Show More
12m 24s
Jun 2024
What’s Inside Your Coronary Arteries? with Anita Vadria, MS, PA-C (Episode 182)
Menopause and age raise our cardiovascular disease risk. Athletes and highly active people also tend to have a higher prevalence of coronary artery calcium and atherosclerotic plaque (though it tends to be the benign kind). But what does that all mean? How can we know what’s real ... Show More
45m 31s
Jan 2024
Left Atrial Appendage Occlusion or Anticoagulation for Stroke Prevention in A Fib
Left Atrial Appendage Occlusion or Anticoagulation for Stroke Prevention in A Fib Guest: Mohamad Adnan (Mohamad) Alkhouli, M.D. Hosts: Malcolm R. Bell, M.D. In this podcast, we will discuss LAAO as an emerging method to reduce stroke risk in patients with atrial fibrillation. We ... Show More
14m 48s